Discussion
T2DM
RECURRENCE, EVENTS, TUMOUR NECROSIS, INFILTRATION
Dapagliflozin has emerged as a powerful agent to reduce the incidence of cardiovascular events in patients with T2DM and HF. Although the mechanisms of dapagliflozin with cardiovascular events have not been fully demonstrated, studies have shown that dapagliflozin can reduce the production of the inflammatory cytokines interleukin-6 and tumour necrosis factor-α and limit macrophage infiltration in a normoglycaemic rabbit model, which exerts its anti-inflammatory effect.The relationship between the incidence of new-onset AF and SGLT2i treatment has been previously reported. Early retrospective studies showed that there was no significant difference between SGLT2i treatment and other hypoglycaemic agents,In conclusion, the DETAIL-CMIV study is the first dedicated clinical trial to demonstrate the preventive effects of dapagliflozin on the recurrence of AF in patients who need CMIV procedures with and without T2DM or HF. The results of this study may have a large impact on the treatment application of dapagliflozin.